Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay

Assays to identify infectious organisms are critical for diagnosis and enabling the development of therapeutic agents. The demonstration that individuals with a 32‐bp deletion within the CCR5 locus were resistant to human immunodeficiency virus (HIV) infection, while those heterozygous for the mutat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of the New York Academy of Sciences 2015-06, Vol.1346 (1), p.7-17
Hauptverfasser:	van der Ryst, Elna, Heera, Jayvant, Demarest, James, Knirsch, Charles
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-HIV Agents - chemical synthesis Anti-HIV Agents - chemistry Anti-HIV Agents - therapeutic use antiretroviral assay Biological Assay - methods Clinical Trials as Topic Cyclohexanes - chemical synthesis Cyclohexanes - chemistry Cyclohexanes - pharmacology diagnostic Drug Design Drug Evaluation, Preclinical - methods HIV HIV Infections - drug therapy HIV-1 - drug effects HIV-1 - physiology Human immunodeficiency virus Humans Receptors, CCR5 - drug effects Receptors, CCR5 - metabolism Triazoles - chemical synthesis Triazoles - chemistry Triazoles - pharmacology tropism Viral Tropism - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!